Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Open access
Agache, Ioana, Beltran, Jessica, Akdis, Cezmi, Akdis, Mubeccel, Canelo‐Aybar, Carlos, Canonica, Giorgio Walter, Casale, Thomas, Chivato, Tomas, Corren, Jonathan, Del Giacco, Stefano, Eiwegger, Thomas, Firinu, Davide, Gern, James E., Hamelmann, Eckard, Hanania, Nicola, Mäkelä, Mika, Hernández‐Martín, Irene, Nair, Parameswaran, O'Mahony, Liam, Papadopoulos, Nikolaos G., Papi, Alberto, Park, Hae‐Sim, Pérez de Llano, Luis, Posso, Margarita, Rocha, Claudio, Quirce, Santiago, Sastre, Joaquin, Shamji, Mohamed, Song, Yang, Steiner, Corinna, Schwarze, Jurgen, Alonso‐Coello, Pablo, Palomares, Oscar, Jutel, Marek·2020·Allergy

Abstract

Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma‐related outcomes were evaluated for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using GRADE. 19 RCTs (three RCTs for benralizumab, three RCTs for dupilumab, three RCTs for mepolizumab, five RCTs for omalizumab and five RCTs for reslizumab), including subjects 12 to 75 years old (except for omalizumab including also subjects 6‐11 years old), ranging from 12 to 56 weeks were evaluated. All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab incidence rate ratio (IRR) 0.53 (95% CI 0.39 to 0.72), dupilumab (IRR) 0.43 (95% CI 0.32 to 0.59), mepolizumab IRR 0.49 (95% CI 0.38 to 0.66), omalizumab (IRR) 0.56 (95% CI 0.40 to 0.77) and reslizumab (IRR) 0.46 (95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve asthma control, QoL and FEV 1, without reaching the minimal important difference (moderate certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug‐related adverse events (AE) and drug‐related serious AE (low to very low certainty of evidence). The incremental cost‐effectiveness ratio per quality‐adjusted life year value is above the willingness to pay threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in hospitalizations, emergency and primary care visits. There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is moderate certainty for improving asthma control, QoL, FEV 1. More data on long‐term safety are needed together with more efficacy data in the paediatric population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/all.14221

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 408

Metadata

Authors
Agache, I., Beltran, J., Akdis, C., Akdis, M., Canelo‐Aybar, C., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Del Giacco, S., Eiwegger, T., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Mäkelä, M., Hernández‐Martín, I., Nair, P., O'Mahony, L., Papadopoulos, N. G., Papi, A., Park, H., Pérez de Llano, L., Posso, M., Rocha, C., Quirce, S., Sastre, J., Shamji, M., Song, Y., Steiner, C., Schwarze, J., Alonso‐Coello, P., Palomares, O., & Jutel, M.
Venue
Allergy
Publisher
Wiley
Published
2020-02-24
Volume
75
Issue
5
Pages
1023-1042
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W3004838051
Cited by
408
References
55
FWCI
10.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.